Results 11 to 20 of about 10,093 (182)

Efficacy and safety of omalizumab against chronic spontaneous urticaria: Real-world study from China

World Allergy Organization Journal, 2022
Background: Omalizumab is an effective treatment for chronic spontaneous urticaria (CSU) patients aged ≥12 years, but its efficacy in patients aged
Ao Wang, MD, Yuhui Yun, MM, Zhihua Wen, MM, Yingxia Gao, BS, Shuzhen Qi, MD, Yu Zhang, MD, Yunsheng Liang, MD, Xu Yao, MD   +7 more
doaj   +1 more source

Description of Baseline Characteristics of Pediatric Allergic Asthma Patients Including those Initiated on Omalizumab

Allergy & Rhinology, 2018
Background Indication of omalizumab in the United States was recently extended to include pediatric (6–11 years) uncontrolled moderate-to-severe allergic asthma patients.
Abhishek Kavati, Dominic Pilon, Benjamin Ortiz, Brandee Paknis, Ashok Vegesna, Bradd Schiffman, Maryia Zhdanava, Patrick Lefebvre, Brian Stone   +8 more
doaj   +1 more source

Cost-effectiveness of omalizumab in real world uncontrolled allergic asthma patients

Pulmonology, 2021
Objective To estimate the cost-effectiveness of omalizumab compared with standard of care in the treatment and control of severe persistent asthma, using the outcomes from the Portuguese subpopulation of the eXpeRience registry.Methods This was a ...
A. Arrobas, M.P. Barbosa, S. Rabiais, B. Vandewalle, J. Félix   +4 more
doaj   +3 more sources

Development of Assay for Determining Free IgE Levels in Serum from Patients Treated with Omalizumab

Allergology International, 2014
Background: Omalizumab, a monoclonal anti-IgE antibody, is currently indicated for the treatment of moderate-to-severe allergic asthma. To measure active IgE levels in sera from patients treated with omalizumab, the IgE subfraction in complex with ...
Reiko Ito, Yasuhiro Gon, Satoshi Nunomura, Ryo Atsuta, Norihiro Harada, Tomohiro Hattori, Shuichiro Maruoka, Yoshimichi Okayama, Chisei Ra, Shu Hashimoto   +9 more
doaj   +1 more source

Omalizumab and IgE in the Control of Severe Allergic Asthma

Frontiers in Pharmacology, 2022
Omalizumab, a human immunoglobulin (Ig)G1 antibody against IgE, is a therapeutic agent for bronchial asthma. The Global Initiative for Asthma guidelines indicate that the use of omalizumab should be considered as an option in step 5 of treatment for ...
Yasuhiro Gon, Shuichiro Maruoka, Kenji Mizumura   +2 more
doaj   +1 more source

Omalizumab, the first available antibody for biological treatment of severe asthma: more than a decade of real-life effectiveness

Therapeutic Advances in Respiratory Disease, 2018
Omalizumab was the first, and for a long time the only available monoclonal antibody for the add-on treatment of severe allergic asthma. In particular, omalizumab selectively targets human immunoglobulin (Ig)E, forming small-size immune complexes that ...
Corrado Pelaia, Cecilia Calabrese, Rosa Terracciano, Francesco de Blasio, Alessandro Vatrella, Girolamo Pelaia   +5 more
doaj   +1 more source

A multicenter approach to evaluate omalizumab effectiveness in Samter’s triad

Monaldi Archives for Chest Disease, 2020
Omalizumab proved to be very effective in improving control of severe atopic asthma. Many small-sized studies suggested a potential role for omalizumab in the management of aspirin-exacerbated respiratory disease. The aim of this study is to describe the
Paolo Cameli, Miriana d'Alessandro, Laura Bergantini, Elena Silvestri, Arianna Romaldi, Giacomo Emmi, Paola Parronchi, Elena Bargagli   +7 more
doaj   +1 more source

Membrane‐Active Peptide Protects Against Inflammation by Targeting NLRP3 Activation at the Trans‐Golgi Network

Advanced Science, EarlyView.
The membrane‐active peptide Pep19‐2.5 reduces harmful inflammation by blocking activation of the NLRP3 inflammasome at trans‐Golgi network membranes. By targeting key membrane interactions, Pep19‐2.5 suppresses inflammatory IL‐1β production and alleviates allergic airway inflammation in mice, leading to reduced immune cell infiltration and improved ...
Jonas Engelhardt, Nico Kirsch, Aileen Kerfin, Lars P. Lunding, Dominic Ferber, Hannes Buthmann, Ilka Schreier, Carlotta Bosio, Ann‐Kathrin Dobbelstein, Anna Klawonn, Rebecca C. Coll, Lena Bauernhofer, Sandro Keller, Matthias Geyer, Michael Wegmann, Andra B. Schromm, Günther Weindl   +16 more
wiley   +1 more source

Solar Urticaria: An Ambispective Study in a Long-term Follow-up Cohort with Emphasis on Therapeutic Predictors and Outcomes

Acta Dermato-Venereologica
Solar urticaria is a rare photodermatosis with several unknown pathogenic, clinical and therapeutic aspects. This study analysed the clinical and therapeutic features of a long-term follow-up solar urticaria cohort, with a focus on omalizumab management ...
David Pesqué, Andrea Ciudad, Evelyn Andrades, Dulce Soto, Ramon Gimeno, Ramon M. Pujol, Ana M. Giménez-Arnau   +6 more
doaj   +1 more source

Pharmacokinetic equivalence of CT‐P39 and reference omalizumab in healthy individuals: A randomised, double‐blind, parallel‐group, Phase 1 trial

Clinical and Translational Allergy, 2022
Background CT‐P39 is being developed as a biosimilar of reference omalizumab. This study aimed to assess the pharmacokinetic equivalence of CT‐P39 to European Union‐approved and United States‐licensed reference omalizumab (EU‐ and US‐omalizumab ...
Marcus Maurer, Sarbjit S. Saini, Kristi McLendon, Paul Wabnitz, Sunghyun Kim, Keumyoung Ahn, Suyoung Kim, Sewon Lee, Clive Grattan   +8 more
doaj   +1 more source